GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Small and Large Bowel/Peyer’s Patch B Cells Drive Celiac Disease Autoimmunity

Peyer’s Patch B Cells Drive Celiac Disease Autoimmunity

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2025

Quick Answer

Yes, Peyer’s patch B cells play a critical role in driving celiac disease autoimmunity. Here is a detailed explanation based on the context provided: ### 1.


Yes, Peyer’s patch B cells play a critical role in driving celiac disease autoimmunity. Here is a detailed explanation based on the context provided:

### 1. **Role of Peyer’s Patches in Celiac Disease:**

  • Peyer’s patches are specialized lymphoid tissues located in the small intestine, acting as primary inductive sites for intestinal immune responses.
  • In celiac disease, Peyer’s patches are pivotal in initiating and sustaining the autoimmune response, particularly the production of disease-specific antibodies.

### 2. **TG2-Specific B Cells in Peyer’s Patches:**

  • TG2-specific B cells, which recognize and bind to transglutaminase 2 (TG2), are found in Peyer’s patches and gut-draining mesenteric lymph nodes.
  • These B cells are not tolerized (i.e., they are not rendered inactive or deleted), which allows them to contribute to the autoimmune process in celiac disease.

### 3. **Central T–B Cell Crosstalk:**

  • The pathogenesis of celiac disease depends on the interaction between gluten-specific CD4⁺ T cells and TG2-specific B cells.
  • TG2-specific B cells present gluten peptides to gluten-specific T cells, receiving help in the form of activation signals. This T–B cell cooperation is essential for the production of anti-TG2 autoantibodies.

### 4. **Antigen Sampling and Uptake:**

  • TG2-specific B cells in Peyer’s patches localize in the subepithelial dome (SED), where they directly sample antigens (gluten and TG2) from the gut lumen.
  • These B cells use their B-cell receptor (BCR) to take up TG2 directly, but this uptake is highly specific—it requires catalytically active TG2 and a matching TG2-specific BCR.

### 5. **Amplification of Autoimmune Responses:**

  • Increased levels of luminal TG2, potentially due to conditions like infections or heightened epithelial turnover, may amplify gluten-specific T-cell responses during active disease.
  • This amplification mechanism highlights the significance of Peyer’s patch B cells in perpetuating the immune response in celiac disease.

### 6. **Germinal Center and Extrafollicular Phenotypes:**

  • Activated TG2-specific B cells in Peyer’s patches display germinal center and extrafollicular phenotypes, indicating their involvement in both long-term antibody production and rapid immune responses.

### 7. **Therapeutic Implications:**

  • Given the central role of TG2-specific B cells in Peyer’s patches, targeting these cells or blocking TG2 activity could serve as a potential therapeutic strategy for celiac disease.
  • Approaches such as inhibiting TG2 enzymatic activity, disrupting T–B cell interactions, or depleting autoreactive B cells are being explored as treatments.

### Conclusion:

Peyer’s patch B cells are key drivers of celiac disease autoimmunity through their ability to recognize TG2, interact with gluten-specific T cells, and produce disease-specific autoantibodies. These findings underscore the importance of Peyer’s patches as critical sites for the initiation and propagation of the autoimmune response in celiac disease.

Related Q&A

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer